Trials / Completed
CompletedNCT04851444
A Study of SI-F019 in Healthy Participants
A Phase I Clinical Study on the Safety, Tolerability and Pharmacokinetics of SI-F019 Recombinant Human Bivalent ACE2-Fc Fusion Protein Injection in a Single Dose in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 36 (actual)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the safety, tolerability and pharmacokinetic properties of a single intravenous administration of SI-F019 recombinant human bivalent ACE2-Fc fusion protein injection in healthy participants, and provide a basis for the design of subsequent clinical trials.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SI-F019 | Single dose is administered IV. |
Timeline
- Start date
- 2021-03-30
- Primary completion
- 2021-09-20
- Completion
- 2021-09-20
- First posted
- 2021-04-20
- Last updated
- 2022-12-13
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04851444. Inclusion in this directory is not an endorsement.